Background: Overexpression of dedicator of cytokinesis 1 (DOCK 1) has been confirmed as an unfavorable prognostic marker in acute myeloid leukemia (AML). 
Purpose: This study is to explore the clinical implications of DOCK1  on AML patients underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). 
Patients and methods: We analyzed 71 de novo AML patients treated with allo-HSCT and divided them into two groups (DOCK1 ^high vs DOCK1 ^low) by the median expression level of DOCK1 . 
Results: High DOCK1  expression was associated with older age (P =0.019), wild-type CEBPA  (P =0.002), IDH1/2  mutations (P =0.010) and RUNX1  mutation (P =0.005). Univariate analyses showed that DOCK1 ^high and RUNX1  mutation were associated with shorter OS (P <0.001, P =0.024). Multivariate analysis confirmed the negative effect of high DOCK1  level on overall survival (P =0.010). 
Conclusion: Our results demonstrate that in AML patients who received allo-HSCT, high DOCK1  expression might have a persistent negative prognostic impact post-transplant.
Keywords: acute myeloid leukemia, allo-HSCT, DOCK1 , prognosis